VTRS

Viatris Inc Ord Shs

• Simply Wall St·5d ago

  What Viatris (VTRS)'s Fast-Acting Pain Drug Filing and Profit Uptick Means For Shareholders

• Reuters·05/19 10:32

  VIATRIS INC. <VTRS.O>: BARCLAYS RAISES TARGET PRICE TO $22 FROM $17

• Dow Jones·05/19 10:13

  Viatris Is Maintained at Overweight by Barclays

• Dow Jones·05/19 10:13

  Viatris Price Target Raised to $22.00/Share From $17.00 by Barclays

• TipRanks·05/19 09:20

  Viatris price target raised to $22 from $17 at Barclays

• TipRanks·05/19 08:37

  Barclays Remains a Buy on Viatris (VTRS)

• Reuters·05/19 07:56

  U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology

• Seeking Alpha·05/18 20:03

  TrumpRx set to expand into generic medicines with Mark Cuban

• NASDAQ·05/18 14:51

  Noteworthy ETF Outflows: DFAT, PR, VTRS, CF

• Seeking Alpha·05/18 12:13

  Large-cap stocks trading at discounted earnings multiples

• TipRanks·05/18 12:09

  Viatris says FDA accepts for review NDA for MR-107A-02

• Benzinga·05/18 12:08

  Viatris' New Drug Application For Moderate-To-Severe Acute Pain Treatment Receives FDA's Acceptance For Review

• PUBT·05/18 12:04

  FDA accepts Viatris fast-acting meloxicam NDA for acute pain review

• Reuters·05/18 12:00

  VIATRIS INC - FDA SETS PDUFA GOAL DATE OF DEC. 27, 2026 FOR VIATRIS FAST-ACTING MELOXICAM

• PR Newswire·05/18 12:00

  U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain